Molecular and cell biology of the prototypic arenavirus LCMV: Implications for understanding and combating hemorrhagic fever arenaviruses

Annals of the New York Academy of Sciences

Volumn 1171, Issue SUPPL. 1, 2009, Pages

  De La Torre, Juan C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

antiviral strategies; arenavirus; hemorrhagic fever; innate immunity; reverse genetics

Indexed keywords

INTERFERON; JUNIN VIRUS VACCINE; LIVE VACCINE; NUCLEOPROTEIN; RIBAVIRIN; UNCLASSIFIED DRUG; VACCINE; ANTIVIRUS AGENT; VIRUS RNA; VIRUS VACCINE;

ADENOVIRUS INFECTION; ADVERSE OUTCOME; ANEMIA; ARENAVIRUS; CONGENITAL DISORDER; CYTOLOGY; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; HEALTH HAZARD; HUMAN; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR BIOLOGY; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; REVIEW; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; ARTICLE; BIOLOGICAL WARFARE; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; LASSA FEVER; PATHOGENICITY; STATISTICS; UNITED STATES; VIRUS INFECTION; VIRUS MENINGITIS;

ARENAVIRUS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRIDAE; ARENAVIRIDAE INFECTIONS; BIOTERRORISM; DISEASE MODELS, ANIMAL; GENOME, VIRAL; HUMANS; LASSA FEVER; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; RIBAVIRIN; RNA, VIRAL; UNITED STATES; VIRAL VACCINES;

EID: 70350450850     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05048.x     Document Type: Review

References (44)

1. Buchmeier, M.J., C.J. Peters & J.C. de La Torre. 2007. Arenaviridae: the viruses and their replication. In Fields Virology. Vol.2, 5th ed. D.M. Knipe & P.M. Holey, Eds.: 1792-1827. Lippincott Williams and Wilkins. Philadelphia.
2. Isaacson, M. 2001. Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 33: 1707-1712.
3. Barton, L.L., M.B. Mets & C.L. Beauchamp. 2002. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am. J. Obstet. Gynecol. 187: 1715-1716.
4. Fischer, S.A. et al. 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354: 2235-2249.
5. Palacios, G. et al. 2008. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 358: 991-998.
6. McCormick, J.B. & S.P. Fisher-Hoch. 2002. Lassa fever. In Arenaviruses I , Vol.262. M.B. Oldstone, Ed.: 75-110. Springer-Verlag. Berlin, Heidelberg, New York.
7. Zinkernagel, R.M. 2002. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263: 1-5.
8. Oldstone, M.B. 2002. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. In Arenaviruses, Vol.263. M.B. Oldstone, Ed.: 83-118. Springer Verlag. Berlin, Heidelberg, New York,Germany.
9. Barber, D.L. et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
10. Flatz, L. et al. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. USA 103: 4663-4668.
11. Sanchez, A.B. & J.C. de La Torre. 2006. Rescue of the prototypic arenavirus LCMV entirely from plasmid. Virology 350: 370-380.
12. de La Torre, J.C. 2008. Reverse genetics approaches to combat pathogenic arenaviruses. Antiviral Res. 80: 239-250.
13. Lee, K.J. et al. 2002. Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J. Virol. 76: 6393-6397.
14. Strecker, T. et al. 2003. Lassa virus Z protein is a matrix protein and sufficient for the release of viruslike particles [corrected]. J. Virol. 77: 10700-10705.
15. Perez, M.,R.C. Craven & J.C. de La Torre. 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. USA 100: 12978-12983.
16. Urata, S. et al. 2006. Cellular factors required for Lassa virus budding. J. Virol. 80: 4191-4195.
17. Freed, E.O. 2002. Viral Late domains. J. Virol. 76: 4679-4687.
18. Perez, M., D.L. Greenwald & J.C. de La Torre. 2004. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J. Virol. 78: 11443-11448.
19. Pinschewer, D.D. et al. 2003. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl. Acad. Sci. USA 100: 7895-7900.
20. Beyer,W.R. et al. 2003. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 77: 2866-2872.
21. Rojek, J.M. & S. Kunz. 2008. Cell entry by human pathogenic arenaviruses. Cell. Microbiol. 10: 828-835.
22. Maiztegui, J.I. et al. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J. Infect. Dis. 177: 277-283.
23. Damonte, E.B. & C.E. Coto. 2002. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Adv. Virus Res. 58: 125-155.
24. Parker,W.B. 2005. Metabolism and antiviral activity of ribavirin. Virus Res. 107: 165-171.
25. Bolken, T.C. et al. 2005. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 69: 86-97.
26. Lee, A.M. et al. 2008. Unique small molecule entry inhibitors of hemorrhagic fever arena viruses. J. Biol. Chem. 283: 18734-18742.
27. Thomas, J.R. & P.J. Hergenrother. 2008. Targeting RNA with small molecules. Chem. Rev. 108: 1171-1224.
28. Ye, X.-S. & L.H. Zhang. 2002. Aminoglycoside mimetics as small-molecule drugs targeting RNA. Curr. Med. Chem. 9: 929-939.
29. Seidah,N.G. et al. 1999. Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc. Natl. Acad. Sci. USA 96: 1321-1326.
30. Rawson, R.B. 2003. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc. Symp. 70: 221-231.
31. Zhang, K. & R.J.Kaufman. 2006. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66: S102-S109.
32. Pornillos, O., J.E. Garrus & W.I. Sundquist. 2002. Mechanisms of envelopedRNAvirus budding. Trends. Cell. Biol. 12: 569-579.
33. Berns, K. et al. 2004. A Large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437.
34. Tannous, B.A. et al. 2005. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11: 435-443.
35. Capul, A.A. & J.C. de La Torre. 2008. A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology 382: 107-114.
36. Ghosh, R.N. et al. 2005. Quantitative cell-based highcontent screening for vasopressin receptor agonistsusing transfluor technology. J. Biomol. Screen. 10: 476-484.
37. Emonet, S.F. et al. 2009. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. USA 106: 3473-3478.
38. Montoya, M. et al. 2005. Rapid activation of spleen dendritic cell subsets following lymphocytic choriomeningitis virus infection of mice: analysis of the involvement of type 1 IFN. J. Immunol. 174: 1851-1861.
39. Malmgaard, L. et al. 2002. Promotion of alpha/beta interferon induction during in vivo viral infection through alpha/beta interferon receptor/STAT1 system-dependent and -independent pathways. J. Virol. 76: 4520-4525.
40. Jung, A. et al. 2008. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response viaMyD88. J. Virol. 82: 196-206.
41. Dalod, M. et al. 2002. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J. Exp. Med. 195: 517-528.
42. Martinez-Sobrido, L. et al. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80: 9192-9199.
43. Martinez-Sobrido, L. et al. 2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81: 12696-12703.
44. Bukowski, J.F., C.A. Biron & R.M.Welsh. 1983. Elevated natural killer cell-mediated cytotoxicity, plasma interferon, and tumor cell rejection in mice persistently infected with lymphocytic choriomeningitis virus. J. Immunol. 131: 991-996.